par Resnier, Pauline;Montier, Tristan;Mathieu, Véronique 
;Benoit, Jean-Pierre;Passirani, Catherine
Référence Biomaterials, 34, 27, page (6429-6443)
Publication Publié, 2013-09
;Benoit, Jean-Pierre;Passirani, CatherineRéférence Biomaterials, 34, 27, page (6429-6443)
Publication Publié, 2013-09
Article révisé par les pairs
| Résumé : | RNA interference currently offers new opportunities for gene therapy by the specific extinction of targeted gene(s) in cancer diseases. However, the main challenge for nucleic acid delivery still remains its efficacy through intravenous administration. Over the last decade, many delivery systems have been developed and optimized to encapsulate siRNA and to specifically promote their delivery into tumor cells and improve their pharmacokinetics for anti-cancer purposes. This review aims to sum up the potential targets in numerous pathways and the properties of recently optimized siRNA synthetic nanomedicines with their preclinical applications and efficacy. Future perspectives in cancer treatment are discussed including promising concomitant treatment with chemotherapies or other siRNA. The outcomes in human clinical trials are also presented. © 2013 Elsevier Ltd. |
